Purpose : Patients with diabetic macular edema are commonly treated with intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents. However, a substantial amount of patients show a suboptimal response to this treatment. It is therefore important to identify poor responders to ...
GDF-15 is part of the transforming growth factor (TGF)-β superfamily and functions as a regulatory cytokine for cell cycle control, development and repair processes in response to e.g. inflammatory processes35,36,37. In preclinical studies, GDF-15 had a wider distribution in the developing ...
While immune checkpoint blockade has greatly improved clinical outcomes in diseases such as melanoma, there remains a need for predictive biomarkers to determine who will likely benefit most from which therapy. To date, most biomarkers of response have b
Immune checkpoint inhibitors (ICI) have revolutionized treatment for various cancers; however, durable response is limited to only a subset of patients. Discovery of blood-based biomarkers that reflect dynamic change of the tumor microenvironment, and predict response to ICI, will markedly improve curre...
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007;99(8):628–38. Article CAS PubMed Google Scholar Gewinner C, Wang ZC, Richardson A, et al. Evidence that inositol polyphosphate 4-phosphatase ...
Is VEGF a pre-dictive biomarker to anti-angiogenic therapy. Otrock Z K,Hatoum H A,Musallam K M.et al. Critical Reviews in Oncology Hematology . 2011Otrock Z K,Hatoum H A,Musallam K M.et al.Is VEGF a pre-dictive biomarker to anti-angiogenic therapy. Critical Reviews in Oncology ...
sFRP2 supersedes VEGF as an age-related driver of angiogenesis in melanoma, affecting response to Anti-VEGF therapy in older patients. Clin Cancer Res. 2020;26(21):5709–19. https://doi.org/10.1158/1078-0432.CCR-20-0446. Article CAS PubMed PubMed Central Google Scholar Ma D, Jiang ...
with M1 TAMs enhancing anti-tumor immunity by secreting anti-inflammatory factors (e.g., IL-12 and TNF-α), and M2 TAMs inhibiting the immune response by secreting pro-inflammatory factors (e.g., IL-10 and TGF-β) and angiogenic factors like VEGF, promoting tumor growth and metastasis [...
However, there remains a subset of patients that do not respond despite their tumors exhibiting PD-L1 expression, which highlights the need for additional biomarkers relevant to response. Here, we review checkpoint inhibitor signal pathways, resistance and sensitivity mechanisms, as well as response ...
Hong et al., Identification of a specific Vimentin isoform that induces an antibody response in pancreatic cancer, Biomarker insights, 1, 175-183, 2006. Ko et al., Expression of the intermediate filament Vimentin in proliferating duct cells as a marker of pancreatic precursor cells, Pancreas, ...